You are here: Home » PTI Stories » National » News
Business Standard

Platypus venom may help treat diabetes: study

Press Trust of India  |  Melbourne 

A hormone produced in the venom of platypus - one of Australia's most iconic native animals - may pave the way for potential new treatments for Type 2 diabetes in humans, a new study suggests.

The hormone, known as glucagon-like peptide-1 (GLP-1), is normally secreted in the gut of both humans and animals, stimulating the release of insulin to lower blood glucose.



However, GLP-1 typically degrades within minutes, researchers from the University of Adelaide and Flinders University in said.

In people with type 2 diabetes, the short stimulus triggered by GLP-1 is not sufficient to maintain a proper blood sugar balance.

As a result, medication that includes a longer lasting form of the hormone is needed to help provide an extended release of insulin.

"Our research team has discovered that monotremes - our iconic platypus and echidna - have evolved changes in the hormone GLP-1 that make it resistant to the rapid degradation normally seen in humans," said Professor Frank Grutzner, from the University of Adelaide's School of Biological Sciences and the Robinson Research Institute.

"We've found that GLP-1 is degraded in monotremes by a completely different mechanism. Further analysis of the genetics of monotremes reveals that there seems to be a kind of molecular warfare going on between the function of GLP-1, which is produced in the gut but surprisingly also in their venom," Grutzner said.

The platypus produces a powerful venom during breeding season, which is used in competition among males for females.

"We've discovered conflicting functions of GLP-1 in the platypus: in the gut as a regulator of blood glucose, and in venom to fend off other platypus males during breeding season. This tug of war between the different functions has resulted in dramatic changes in the GLP-1 system," said Associate Professor Briony Forbes, from Flinders University's School of Medicine.

"The function in venom has most likely triggered the evolution of a stable form of GLP-1 in monotremes. Excitingly, stable GLP-1 molecules are highly desirable as potential type 2 diabetes treatments," she said.

"This is an amazing example of how millions of years of evolution can shape molecules and optimise their function," Grutzner said.

"These findings have the potential to inform diabetes treatment, one of our greatest health challenges, although exactly how we can convert this finding into a treatment will need to be the subject of future research," he said.

GLP-1 has also been discovered in the venom of echidnas. However, while the platypus has spurs on its hind limbs for delivering a large amount of venom to its opponent, there is no such spur on echidnas.

"The lack of a spur on echidnas remains an evolutionary mystery, but the fact that both platypus and echidnas have evolved the same long-lasting form of the hormone GLP-1 is in itself a very exciting finding," Grutzner said.

The study was published in the journal Scientific Reports.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Platypus venom may help treat diabetes: study

A hormone produced in the venom of platypus - one of Australia's most iconic native animals - may pave the way for potential new treatments for Type 2 diabetes in humans, a new study suggests. The hormone, known as glucagon-like peptide-1 (GLP-1), is normally secreted in the gut of both humans and animals, stimulating the release of insulin to lower blood glucose. However, GLP-1 typically degrades within minutes, researchers from the University of Adelaide and Flinders University in Australia said. In people with type 2 diabetes, the short stimulus triggered by GLP-1 is not sufficient to maintain a proper blood sugar balance. As a result, medication that includes a longer lasting form of the hormone is needed to help provide an extended release of insulin. "Our research team has discovered that monotremes - our iconic platypus and echidna - have evolved changes in the hormone GLP-1 that make it resistant to the rapid degradation normally seen in humans," said Professor Frank ... A hormone produced in the venom of platypus - one of Australia's most iconic native animals - may pave the way for potential new treatments for Type 2 diabetes in humans, a new study suggests.

The hormone, known as glucagon-like peptide-1 (GLP-1), is normally secreted in the gut of both humans and animals, stimulating the release of insulin to lower blood glucose.

However, GLP-1 typically degrades within minutes, researchers from the University of Adelaide and Flinders University in said.

In people with type 2 diabetes, the short stimulus triggered by GLP-1 is not sufficient to maintain a proper blood sugar balance.

As a result, medication that includes a longer lasting form of the hormone is needed to help provide an extended release of insulin.

"Our research team has discovered that monotremes - our iconic platypus and echidna - have evolved changes in the hormone GLP-1 that make it resistant to the rapid degradation normally seen in humans," said Professor Frank Grutzner, from the University of Adelaide's School of Biological Sciences and the Robinson Research Institute.

"We've found that GLP-1 is degraded in monotremes by a completely different mechanism. Further analysis of the genetics of monotremes reveals that there seems to be a kind of molecular warfare going on between the function of GLP-1, which is produced in the gut but surprisingly also in their venom," Grutzner said.

The platypus produces a powerful venom during breeding season, which is used in competition among males for females.

"We've discovered conflicting functions of GLP-1 in the platypus: in the gut as a regulator of blood glucose, and in venom to fend off other platypus males during breeding season. This tug of war between the different functions has resulted in dramatic changes in the GLP-1 system," said Associate Professor Briony Forbes, from Flinders University's School of Medicine.

"The function in venom has most likely triggered the evolution of a stable form of GLP-1 in monotremes. Excitingly, stable GLP-1 molecules are highly desirable as potential type 2 diabetes treatments," she said.

"This is an amazing example of how millions of years of evolution can shape molecules and optimise their function," Grutzner said.

"These findings have the potential to inform diabetes treatment, one of our greatest health challenges, although exactly how we can convert this finding into a treatment will need to be the subject of future research," he said.

GLP-1 has also been discovered in the venom of echidnas. However, while the platypus has spurs on its hind limbs for delivering a large amount of venom to its opponent, there is no such spur on echidnas.

"The lack of a spur on echidnas remains an evolutionary mystery, but the fact that both platypus and echidnas have evolved the same long-lasting form of the hormone GLP-1 is in itself a very exciting finding," Grutzner said.

The study was published in the journal Scientific Reports.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Platypus venom may help treat diabetes: study

A hormone produced in the venom of platypus - one of Australia's most iconic native animals - may pave the way for potential new treatments for Type 2 diabetes in humans, a new study suggests.

The hormone, known as glucagon-like peptide-1 (GLP-1), is normally secreted in the gut of both humans and animals, stimulating the release of insulin to lower blood glucose.

However, GLP-1 typically degrades within minutes, researchers from the University of Adelaide and Flinders University in said.

In people with type 2 diabetes, the short stimulus triggered by GLP-1 is not sufficient to maintain a proper blood sugar balance.

As a result, medication that includes a longer lasting form of the hormone is needed to help provide an extended release of insulin.

"Our research team has discovered that monotremes - our iconic platypus and echidna - have evolved changes in the hormone GLP-1 that make it resistant to the rapid degradation normally seen in humans," said Professor Frank Grutzner, from the University of Adelaide's School of Biological Sciences and the Robinson Research Institute.

"We've found that GLP-1 is degraded in monotremes by a completely different mechanism. Further analysis of the genetics of monotremes reveals that there seems to be a kind of molecular warfare going on between the function of GLP-1, which is produced in the gut but surprisingly also in their venom," Grutzner said.

The platypus produces a powerful venom during breeding season, which is used in competition among males for females.

"We've discovered conflicting functions of GLP-1 in the platypus: in the gut as a regulator of blood glucose, and in venom to fend off other platypus males during breeding season. This tug of war between the different functions has resulted in dramatic changes in the GLP-1 system," said Associate Professor Briony Forbes, from Flinders University's School of Medicine.

"The function in venom has most likely triggered the evolution of a stable form of GLP-1 in monotremes. Excitingly, stable GLP-1 molecules are highly desirable as potential type 2 diabetes treatments," she said.

"This is an amazing example of how millions of years of evolution can shape molecules and optimise their function," Grutzner said.

"These findings have the potential to inform diabetes treatment, one of our greatest health challenges, although exactly how we can convert this finding into a treatment will need to be the subject of future research," he said.

GLP-1 has also been discovered in the venom of echidnas. However, while the platypus has spurs on its hind limbs for delivering a large amount of venom to its opponent, there is no such spur on echidnas.

"The lack of a spur on echidnas remains an evolutionary mystery, but the fact that both platypus and echidnas have evolved the same long-lasting form of the hormone GLP-1 is in itself a very exciting finding," Grutzner said.

The study was published in the journal Scientific Reports.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard